Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:6279250.
doi: 10.1155/2016/6279250. Epub 2016 Apr 11.

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario

Affiliations

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario

Haris M Vaid et al. Can Respir J. 2016.

Abstract

Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario's publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n = 251). Combination therapy was used to treat 22.9% (n = 69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96-$747) for those who survived and $2,021 (IQR $993-$6,399) for those who died over a one-year period, respectively (p < 0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management.

PubMed Disclaimer

References

    1. Brown L. M., Chen H., Halpern S., et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry. Chest. 2011;140(1):19–26. doi: 10.1378/chest.10-1166. - DOI - PMC - PubMed
    1. Gatzoulis M. A. Pulmonary Arterial Hypertension. Oxford, UK: Oxford University Press; 2012.
    1. Rich S., Dantzker D. R., Ayres S. M., et al. Primary pulmonary hypertension. A national prospective study. Annals of Internal Medicine. 1987;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. - DOI - PubMed
    1. Thenappan T., Shah S. J., Rich S., Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. European Respiratory Journal. 2007;30(6):1103–1110. doi: 10.1183/09031936.00042107. - DOI - PubMed
    1. Badesch D. B., Raskob G. E., Elliott C. G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376–387. doi: 10.1378/chest.09-1140. - DOI - PubMed

Substances

LinkOut - more resources